Q1 EPS Estimates for Sutro Biopharma Lifted by HC Wainwright

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities researchers at HC Wainwright raised their Q1 2025 earnings estimates for shares of Sutro Biopharma in a report issued on Monday, March 17th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.38) for the quarter, up from their previous forecast of ($0.82). HC Wainwright has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.

Other research analysts have also issued reports about the company. Wells Fargo & Company lowered their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Citizens Jmp cut shares of Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, March 14th. JMP Securities restated a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Wedbush cut shares of Sutro Biopharma from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $2.00 in a report on Friday, March 14th. Finally, Piper Sandler set a $2.00 target price on Sutro Biopharma in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Sutro Biopharma currently has an average rating of “Hold” and an average target price of $6.63.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock opened at $0.82 on Wednesday. Sutro Biopharma has a 1-year low of $0.76 and a 1-year high of $6.13. The business’s fifty day moving average price is $1.69 and its two-hundred day moving average price is $2.66. The company has a market capitalization of $67.68 million, a P/E ratio of -0.51 and a beta of 1.22.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The business had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10.44 million. During the same period last year, the firm posted ($1.78) EPS.

Institutional Trading of Sutro Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in Sutro Biopharma by 16.6% in the fourth quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock worth $74,000 after buying an additional 5,770 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Sutro Biopharma by 6.1% in the 4th quarter. Rhumbline Advisers now owns 126,698 shares of the company’s stock worth $233,000 after acquiring an additional 7,320 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Sutro Biopharma by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after acquiring an additional 10,000 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Sutro Biopharma by 24.8% during the fourth quarter. Wells Fargo & Company MN now owns 52,738 shares of the company’s stock worth $97,000 after purchasing an additional 10,466 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in shares of Sutro Biopharma by 74.3% during the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company’s stock valued at $50,000 after purchasing an additional 11,494 shares during the last quarter. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.